KOP-based Personalized Medicine Company Bringing Innovation to Mental Healthcare

Rep. Brendan Boyle Tours KOP’s Genomind with Eye Toward Mental Healthcare

Source: MONTCO. Today, Mark Hostutler

King of Prussia’s Genomind, a personalized medicine company bringing innovation to mental healthcare, highlighted the importance of the biotech industry to Pennsylvania when Rep. Brendan Boyle toured its lab last month.

Boyle, who represents Pennsylvania’s 13th Congressional District, visited Genomind’s CLIA certified laboratory, where the company performs its proprietary genetic testing focusing on neurotransmitter and metabolism pathways for patients across the country.

Genomind also announced it had reached an important milestone: the 80,000th patient had received results from the company’s Genecept Assay, a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness.

Genecept Assay is an easily administered cheek swab test that analyzes key genes, selected based on the critical examination of hundreds of studies showing that variations in these genes can inform treatment decisions in psychiatry.

Rep. Boyle was also joined on the lab tour by Christopher Molineaux, the President and CEO of Wayne-based Pennsylvania Bio, which works to ensure Pennsylvania is the nation’s hub for the life sciences by creating a business and public policy environment that fosters the growth and success of life sciences.

“Genomind is a shining example of the strength of the life sciences industry in Pennsylvania,” said Molineaux. “The tour with Congressman Boyle showcased the groundbreaking work Genomind is doing and how it greatly contributes to our economy.”